open access

Vol 7, No 4 (2002)
Review paper
Published online: 2002-01-01
Submitted: 2002-03-02
Get Citation

Cancer gene therapy – state-of-the-art

Piotr J. Wysocki, Małgorzata Mackiewicz-Wysocka, Andrzej Mackiewicz
DOI: 10.1016/S1507-1367(02)70989-9
·
Rep Pract Oncol Radiother 2002;7(4):149-155.

open access

Vol 7, No 4 (2002)
Review paper
Published online: 2002-01-01
Submitted: 2002-03-02

Abstract

A number of gene therapy clinical trials are being carried out the world over. Gene therapy is being applied in (I) cancer diseases, involving the largest number of patients, (II) monogenic diseases, (III) infectious diseases, (IV) vascular diseases, (V) autoimmune diseases and others. In the last decade, several strategies of cancer gene therapy have emerged due to a rapid development of gene delivery systems, both viral (recombinant retroviruses, adenoviruses, AAVs, herpes viruses) and nonviral (liposomes, gene guns, electroporation). To date four main strategies of cancer gene therapy have been evaluated in clinical trials: (I) immunogene therapy, (II) suicide gene therapy, (III) antiangiogenic gene therapy, (IV) and administration of tumour suppressor genes.

These strategies mostly involve: malignant melanoma, prostate cancer, renal cell cancer, colon cancer, breast and ovarian cancers, lung cancers, neoplastic diseases of the blood and brain tumours.

At the Department of Cancer Immunology at the GreatPoland Cancer Center Gene Modified Tumour Vaccine has been tested in malignant melanoma patients for more than six years. Due to encouraging results from phase I and II of clinical trials a phase III was designed and will be started in 2003.

Abstract

A number of gene therapy clinical trials are being carried out the world over. Gene therapy is being applied in (I) cancer diseases, involving the largest number of patients, (II) monogenic diseases, (III) infectious diseases, (IV) vascular diseases, (V) autoimmune diseases and others. In the last decade, several strategies of cancer gene therapy have emerged due to a rapid development of gene delivery systems, both viral (recombinant retroviruses, adenoviruses, AAVs, herpes viruses) and nonviral (liposomes, gene guns, electroporation). To date four main strategies of cancer gene therapy have been evaluated in clinical trials: (I) immunogene therapy, (II) suicide gene therapy, (III) antiangiogenic gene therapy, (IV) and administration of tumour suppressor genes.

These strategies mostly involve: malignant melanoma, prostate cancer, renal cell cancer, colon cancer, breast and ovarian cancers, lung cancers, neoplastic diseases of the blood and brain tumours.

At the Department of Cancer Immunology at the GreatPoland Cancer Center Gene Modified Tumour Vaccine has been tested in malignant melanoma patients for more than six years. Due to encouraging results from phase I and II of clinical trials a phase III was designed and will be started in 2003.

Get Citation

Keywords

cancer gene therapy; viral vectors; immnotherapy; antiangiogeic therapy; suicide therapy

About this article
Title

Cancer gene therapy – state-of-the-art

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 7, No 4 (2002)

Pages

149-155

Published online

2002-01-01

DOI

10.1016/S1507-1367(02)70989-9

Bibliographic record

Rep Pract Oncol Radiother 2002;7(4):149-155.

Keywords

cancer gene therapy
viral vectors
immnotherapy
antiangiogeic therapy
suicide therapy

Authors

Piotr J. Wysocki
Małgorzata Mackiewicz-Wysocka
Andrzej Mackiewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl